Precision oncology company developing blood-based cancer testing for treatment selection, recurrence monitoring and screening.
Profile & Fundamentals
Guardant Health: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Guardant Health Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Company profile record
Guardant Health Inc
Common Stock · Health Care · Health Care Services
Company
- Company / asset
- Guardant Health Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Services
- HQ
- 🇺🇸 United States
- Head office
- 3100 Hanover Street, Palo Alto, CA, United States, 94304
Leadership & scale
- Chief executive
- Dr. Helmy Eltoukhy Ph.D.
- CEO year born
- 1979
- Full-time employees
- 2.5K
- Fiscal year end
- December
- IPO date
- 2018-10-04
Fundamentals snapshot
- Market Cap
- USD 22.5B
- P/E
- --
- Revenue (Q2 26)
- USD 335.0M
- Profit (Q2 26)
- USD -120.1M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 982.0M
- Shares in public float
- 129.5M
- Insider ownership
- 3.97%
Reporting & identifiers
- Symbol
- GH.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US40131M1099
- Asset ID
- equity_cbe83dd8-f8f9-55d0-8d8d-e2f286836bc8
Ownership
Shares Outstanding
Latest: 132.1M | Max: 132.1M | Min: 70.7M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
98.03%
129.5M latest reported shares
Insider Ownership
3.97%
Latest reported insider stake
Short Float
0.09%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 70,716,000 |
| 2018-01-01 | 84,123,000 |
| 2019-01-01 | 93,997,000 |
| 2020-01-01 | 100,018,000 |
| 2021-01-01 | 101,697,000 |
| 2022-01-01 | 102,516,000 |
| 2023-01-01 | 118,508,000 |
| 2024-01-01 | 123,754,000 |
| 2025-01-01 | 128,657,000 |
| 2026-01-01 | 132,074,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 11,553,759 | 8.61% | 2026-03-31 |
| T. Rowe Price Associates, Inc. | 7,023,689 | 5.23% | 2026-03-31 |
| Vanguard Portfolio Management, LLC | 5,837,992 | 4.35% | 2026-03-31 |
| Vanguard Capital Management, LLC | 5,624,180 | 4.19% | 2026-03-31 |
| Amvescap Plc. | 4,946,469 | 3.69% | 2026-03-31 |
| The Goldman Sachs Group Inc | 4,435,839 | 3.31% | 2026-03-31 |
| FMR Inc | 4,116,081 | 3.07% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4,002,749 | 2.98% | 2026-08-31 |
| Two Sigma Investments LLC | 3,719,301 | 2.77% | 2026-06-30 |
| Geode Capital Management, LLC | 3,508,883 | 2.61% | 2026-03-31 |
| Franklin Templeton Inc | 3,448,193 | 2.57% | 2026-03-31 |
| Capital Research & Mgmt Co - Division 3 | 3,399,604 | 2.53% | 2026-06-30 |
| Deep Track Capital, LP | 3,393,312 | 2.53% | 2026-06-30 |
| Vanguard Small Cap Index | 2,898,392 | 2.16% | 2026-08-31 |
| State Street Corp | 2,884,620 | 2.15% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Top-line revenue demonstrates explosive momentum, driven by rapid adoption of Shield colorectal screening and double-digit volume expansion in therapy selection testing. Recent quarters show revenue growing over forty percent year-over-year, confirming robust physician demand for non-invasive liquid biopsy options. However, this revenue expansion conceals persistent operational unprofitability. Heavy selling, general, and administrative expenditures required to detail decentralized primary care physicians continue to devour gross profits. With annual net losses exceeding four hundred million dollars and negative free cash flow, top-line growth remains subsidized by balance sheet liquidity rather than self-funding operations.
Top-line revenue demonstrates explosive momentum, driven by rapid adoption of Shield colorectal screening and double-digit volume expansion in therapy selection testing. Recent quarters show revenue growing over forty percent year-over-year, confirming robust physician demand for non-invasive liquid biopsy options. However, this revenue expansion conceals persistent operational unprofitability. Heavy selling, general, and administrative expenditures required to detail decentralized primary care physicians continue to devour gross profits. With annual net losses exceeding four hundred million dollars and negative free cash flow, top-line growth remains subsidized by balance sheet liquidity rather than self-funding operations.
Revenue, Net Income, and Free Cash Flow
Latest: USD 982.0M | Max: USD 982.0M | Min: USD -654.6M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Gross profit margins have expanded toward sixty-seven percent, demonstrating authentic manufacturing efficiency as automated sequencing platforms and chemistry optimizations reduce unit processing costs per sample. The core laboratory engine exhibits favorable contribution economics on each test processed. Conversely, operating margins remain deeply submerged in negative territory due to massive commercialization overhead. Selling blood-based screening tests across tens of thousands of family doctors requires an extensive commercial salesforce and marketing expenditure. Sustainable operating profitability depends on physician ordering habits becoming self-sustaining without requiring proportional increases in commercial spending.
Gross profit margins have expanded toward sixty-seven percent, demonstrating authentic manufacturing efficiency as automated sequencing platforms and chemistry optimizations reduce unit processing costs per sample. The core laboratory engine exhibits favorable contribution economics on each test processed. Conversely, operating margins remain deeply submerged in negative territory due to massive commercialization overhead. Selling blood-based screening tests across tens of thousands of family doctors requires an extensive commercial salesforce and marketing expenditure. Sustainable operating profitability depends on physician ordering habits becoming self-sustaining without requiring proportional increases in commercial spending.
Profitability Margins
Latest: 64.5% | Max: 67.7% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
64.5%
Gross profit / revenue
Operating Margin
-44.5%
Operating income / revenue
Net Margin
-42.4%
Net income / revenue
FCF Margin
-23.7%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 25,249,000 | -46,139,000 | -38,476,000 |
| 2017-12-31 | 49,842,000 | -83,221,000 | -81,218,000 |
| 2018-12-31 | 90,639,000 | -85,063,000 | -92,388,000 |
| 2019-12-31 | 214,375,000 | -75,651,000 | -68,419,000 |
| 2020-12-31 | 286,730,000 | -253,783,000 | -157,986,000 |
| 2021-12-31 | 373,653,000 | -405,670,000 | -284,052,000 |
| 2022-12-31 | 449,538,000 | -654,588,000 | -386,924,000 |
| 2023-12-31 | 563,948,000 | -479,449,000 | -345,461,000 |
| 2024-12-31 | 739,016,000 | -436,373,000 | -274,943,000 |
| 2025-12-31 | 982,021,000 | -416,277,000 | -233,066,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 12.38 | -173.66 | -182.74 | -152.39 |
| 2017-12-31 | 36.56 | -153.71 | -166.97 | -162.95 |
| 2018-12-31 | 52.33 | -102.54 | -93.85 | -101.93 |
| 2019-12-31 | 67.01 | -38.42 | -35.29 | -31.92 |
| 2020-12-31 | 67.73 | -88.92 | -88.51 | -55.1 |
| 2021-12-31 | 67.11 | -110 | -108.57 | -76.02 |
| 2022-12-31 | 65.23 | -121.1 | -145.61 | -86.07 |
| 2023-12-31 | 59.74 | -100.14 | -85.02 | -61.26 |
| 2024-12-31 | 60.79 | -60.02 | -59.05 | -37.2 |
| 2025-12-31 | 64.46 | -44.53 | -42.39 | -23.73 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.